Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Says PD-L1 Testing Already On The Rise, Setting Stage For First-Line Launch

Executive Summary

Testing for the biomarker has picked up since paradigm changing data in first-line lung cancer was presented at ESMO, management said. Now, with the FDA approval of Keytruda, Merck is focused on establishing a solid lead in a big commercial market.


Related Content

Merck's Keytruda Reaches Blockbuster Status, But Still Lags In Lung Cancer
PD-1 Deep Dive: Lung Cancer Market Braced For Change
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
Bristol Still Rules Immuno-Oncology, But For How Long?
Merck: As The Sun Rises For Keytruda, It Sets For Zetia/Vytorin
It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Merck Oncology Strategy: With First-Line Lung Data, A New Day Dawns For Keytruda


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts